Coverage and association with clinical variables of antipneumococcal vaccination of the population over 65 years-old in Tarragona-valls;Cobertura y asociación con variables clínicas de la vacunación antineumocócica en la población mayor de 65 años de Tarragona-valls

Revista Espanola de Salud Publica

Volumn 79, Issue 6, 2005, Pages 645-654

  Vila Córcoles, Angel ^a,b   Ochoa Gondar, Olga ^a   Ansa Echeverría, Xabier ^a   Bladé Creixenti, Jordi ^a   Palacios Llamazares, Laura ^a   Fuentes Bellido, Cruz María ^a  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b NONE   (Spain)

Author keywords

Elderly Community acquired infection; Immunizations Coverage; Pneumococcal vaccines

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGED; ALCOHOLISM; ARTICLE; CHRONIC LIVER DISEASE; CHRONIC LUNG DISEASE; CLINICAL RESEARCH; CONTROLLED STUDY; HEALTH CENTER; HEALTH PROGRAM; HEART DISEASE; HUMAN; MEDICAL RECORD; NEOPLASM; PNEUMONIA; POPULATION; RISK FACTOR; SMOKING; VACCINATION; AGE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; LOBAR PNEUMONIA; MALE; PREVENTIVE HEALTH SERVICE; SEX DIFFERENCE; SPAIN; STATISTICAL ANALYSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; SEX FACTORS; SPAIN; VACCINATION;

EID: 33644869082     PISSN: 11355727     EISSN: 11355727     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Almirall J, Bolíbar I, Vidal J, Sauca G, Coll P, Niklasson B et al. Epidemiology of community-adquired pneumonia in adults: a population-based study. Eur Respir J 2000; 15: 757-63.
2. Santos de Unamuno C, Llorente MA, Carandell E, Gutiérrez M, Riera J, Ramírez A, et al. Lugar de atención, etiología, y tratamiento de las neumonías adquiridas en la comunidad de Palma de Mallorca. Med Clin (Barc) 1998; 110: 290-4.
3. Domínguez A, Salleras L, Cardenosa N, Ciruela P, Carmona G, Martínez A, Torner N, Fuentes M. The epidemiology of invasive Streptococcus pneumoniae disease in Catalonia (Spain). A hospital-based study. Vaccine 2002; 20: 2989-94
4. Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Sociedad Española de Quimioterapia (SEQ), Sociedad Española de Medicina Interna (SEMI) y Sociedad Española de Medicina de Urgencias y Emergencias (SEMES). Tratamiento antibiótico empírico de la neumonía adquirida en la comunidad en el paciente adulto inmunocompetente. Rev Esp Quimioter 2003; 16: 457-66.
5. Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med. 2004; 117 (Suppl 3A): 3S-15S.
6. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24.
7. Pneumococcal vaccines. WHO position paper. World Health Organization. Wkly Epidemiol Rec 2003; 78: 110-119.
8. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, Detsky AS, Kapoor WN. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-77.
9. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician 1999; 45: 2381-93.
10. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000; 1: 1.
11. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine. 2001; 19: 4780-90.
12. Puig J, Belenguer A, Goterris M, Brines MJ. Efectividad de la vacuna frente al neumococo en el anciano. Revision sistemática y metaanálisis. Aten Primaria 2002; 30: 269-83.
13. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003; 3: 71-8.
14. Fedson DS, Lise C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22: 927-46.
15. Center for Disease Control and Prevention: Influenza and pneumococcal vaccination coverage among persons aged > or =65 years and persons aged 18-64 years with diabetes or asthma - United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53 (43):1007-12.
16. Salleras Ll, Urbiztondo Ll, Fernández N, Comín E, Sánchez F, Batalla J et al. Vacunación antineumocócica en las personas mayores. Med Clin (Barc) 2001; 116: 18-23.
17. Plans P. Coste-efectividad de la vacunación antineumocócica 23-valente en Cataluña. Gac Sanit 2002; 15 (5): 392-400.
18. Gómez Marco JJ. Vacuna neumocócica en mayores de 65 años: la incertidumbre continúa. Aten Primaria 2003; 32 (supl 1): 74-5.
19. Aller AI, Garjón FJ, Buisán MJ, Palacín JC. ¿Está justificada la vacunación contra el neumococo en mayores de 65 años?. Aten Primaria 2002; 7: 433-7.
20. Generalitat de Catalunya. Plà de Salut de Catalunya 1999-2001. Generalitat de Catalunya, Barcelona 2000.
21. Batalla J, Urbiztomdo L, Ciruela P, Martínez M, Boldu M. Cobertura vacunal antineumocócica en la población mayor de 65 años de Cataluña. En: Campins M, Moraga F. Vacunas. Barcelona, Prous Science 2002; p. 173-80
22. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270: 1826-31.
23. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol. 2004; 19 (4): 353-63.
24. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysacharyde vaccine in older adults. N Engl J Med 2003; 348: 1747-55.
25. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J. 2004; 23 (3): 363-8.
26. Zimmerman RK, Raymund M, Janosky JE, Nowalk MP, Fine MJ. Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine 2003;21:1486-91.
27. Hoover DR, Sambamoorthi U, Crystal S. Characteristics of community dwelling elderly not vaccinated for pneumococcus in 1998 and 2001. Prev Med 2004; 39 (3): 517-27.
28. Daniels NA, Nguyen TT, Gildengorin G, Perez-Stable EJ. Adult immunization in university-based primary care and specialty practices.J Am Geriatr Soc 2004; 52 (6): 1007-12.
29. Zimmerman RK, Santibanez TA, Fine MA, et al. Barriers and facilitators of pneumococcal vaccination among the elderly. Vaccine 2003; 2001: 1510-17.
30. Dear K, Holden J, Andrews R, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003; (4): CD000422.
31. Domínguez A, Salleras L, Fedson DS, Izquierdo C, Ruiz L, Ciruela P, Fenoll A, Casal J. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis. 2005; 40 (9): 1250-7.
32. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278: 1333-9.
33. Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis. 2000; 31: 444-50.